Vanguard Global Advisers
NUVB icon

Vanguard Global Advisers’s Nuvation Bio NUVB Stock Holding History

Vanguard Global Advisers’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Buy
133,622
+10,460
+8% +$51.1K ﹤0.01% 1905
2026
Q1 		$528K Buy
+123,162
New +$686K ﹤0.01% 2014

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Global Advisers's NUVB Position: Q2 2026 in Review

Vanguard Global Advisers increased its Nuvation Bio (NUVB) stake by 8.5% in Q2 2026, buying an estimated $51.1K and bringing the position to 133,622 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

Vanguard Global Advisers first reported a position in NUVB in Q1 2026 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Vanguard Global Advisers held 133,622 shares of Nuvation Bio worth $759K as of Q2 2026.
  • Vanguard Global Advisers bought 10,460 Nuvation Bio shares in Q2 2026, an estimated $51.1K.
  • Nuvation Bio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1905 holding.
  • Vanguard Global Advisers first reported a position in Nuvation Bio in Q1 2026 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.